Acute hepatitis C in HIV-infected individuals: Recommendations from the European AIDS Treatment Network (NEAT) consensus conference: The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel

AIDS

Volumn 25, Issue 4, 2011, Pages 399-409

  Rockstroh, Jürgen K ^a  

^a NONE

Author keywords

acute hepatitis; hepatitis C; HIV; interferon; intravenous drug abuse; MSM; ribavirin

Indexed keywords

HEPATITIS C ANTIBODY; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ACUTE HEPATITIS; ADAPTIVE IMMUNITY; ANTIVIRAL THERAPY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; EUROPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; MORBIDITY; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; RISK REDUCTION; SCREENING TEST; VIRAL CLEARANCE; VIRUS DETECTION; VIRUS LOAD; VIRUS TRANSMISSION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEPATITIS C; HIV INFECTIONS; HUMANS;

EID: 79951513576     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328343443b     Document Type: Conference Paper

References (83)

1. van de Laar TJ, Matthews GV, Prins M, Danta M. Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 2010; 24:1799-1812.
2. The periodic health examination. Canadian Task Force on the Periodic Health Examination. Can Med Assoc J 1979, 121: 1193-1254.
3. Matthews GV, Hellard M, Haber P, Yeung B, Marks P, Baker D, et al. Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009; 48:650-658.
4. Vogel M, Deterding K, Wiegand J, Gruner NH, Baumgarten A, Jung MC, et al. Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infection. Clin Infect Dis 2009; 49:317-319; author reply 319.
5. Sagnelli E, Coppola N, Marrocco C, Coviello G, Battaglia M, Messina V, et al. Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. J Hepatol 2005; 42:646-651.
6. Coppola N, Pisapia R, Marrocco C, Martini S, Vatiero LM, Messina V, et al. Anti-HCV I (Pubitemid 47419428)
7. Coppola N, Pisapia R, Tonziello G, Masiello A, Martini S, Pisaturo M, et al. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol 2009; 46:222-229.
8. Thomson EC, Nastouli E, Main J, Karayiannis P, Eliahoo J, Muir D, McClure MO. Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009; 23:89-93.
9. Cicconi P, Cozzi-Lepri A, Phillips A, Puoti M, Antonucci G, Manconi PE, et al. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS 2007; 21:599-606.
10. Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999; 31 (Suppl 1):9-16. (Pubitemid 30002685)
11. McGovern BH, Birch CE, Bowen MJ, Reyor LL, Nagami EH, Chung RT, Kim AY. Improving the diagnosis of acute hepatitis C virus infection with expanded viral load criteria. Clin Infect Dis 2009; 49:1051-1060.
12. Nastouli E, Thomson EC, Karayiannis P, Main J, McClure M, Muir D. Diagnosing acute hepatitis C in HIV-infected patients: nucleic acid testing compared with antibody and antigen-antibody detecting methods. J Clin Virol 2009; 44:78-80.
13. MederackeI,WedemeyerH,CiesekS,SteinmannE, Raupach R, Wursthorn K, et al. Performance and clinical utility of a novel fully automated quantitative HCV-core antigen assay. J Clin Virol 2009; 46:210-215.
14. Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based anti-retroviral regimens with or without concurrent ritonavir. AIDS 2004; 18:2277-2284. (Pubitemid 39620220)
15. Balogun MA, Ramsay ME, Hesketh LM, Andrews N, Osborne KP, Gay NJ, Morgan-Capner P. The prevalence of hepatitis C in England and Wales. J Infect 2002; 45:219-226. (Pubitemid 36104853)
16. Rockstroh JK, Mocroft A, Soriano V, Tural C, Losso MH, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992-1002. (Pubitemid 41266795)
17. Larsen C, Pialoux G, Salmon D, Antona D, Le Strat Y, Piroth L, et al. Prevalence of hepatitis C and hepatitis B infection in the HIV-infected population of France, 2004. Euro Surveill 2008, 13.
18. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837. (Pubitemid 34194855)
19. Tedaldi EM, Hullsiek KH, Malvestutto CD, Arduino RC, Fisher EJ, Gaglio PJ, et al. Prevalence and characteristics of hepatitis C virus coinfection in a human immunodeficiency virus clinical trials group: the Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis 2003; 36:1313-1317. (Pubitemid 36637091)
20. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfec-tion increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis 2004; 39:1507-1513. (Pubitemid 39518216)
21. Strasfeld L, Lo Y, Netski D, Thomas DL, Klein RS. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr 2003; 33:356-364. (Pubitemid 36859062)
22. Rauch A, Rickenbach M, Weber R, Hirschel B, Tarr PE, Bucher HC, et al. Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. Clin Infect Dis 2005; 41:395-402. (Pubitemid 41022120)
23. Jin F, Prestage GP, Matthews G, Zablotska I, Rawstorne P, Kippax SC, et al. Prevalence, incidence and risk factors for hepatitis C in homosexual men: data from two cohorts of HIV-negative and HIV-positive men in Sydney, Australia. Sex Transm Infect 2010; 86:25-28.
24. Urbanus AT, van de Laar TJ, Stolte IG, Schinkel J, Heijman T, Coutinho RA, Prins M. Hepatitis C virus infections among HIV-infected men who have sex with men: an expanding epidemic. AIDS 2009; 23:F1-F7.
25. Frederick T, Burian P, Terrault N, Cohen M, Augenbraun M, Young M, et al. Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS 2009; 23:915-923.
26. Alary M, Joly JR, Vincelette J, Lavoie R, Turmel B, Remis RS. Lack of evidence of sexual transmission of hepatitis C virus in a prospective cohort study of men who have sex with men. Am J Public Health 2005; 95:502-505. (Pubitemid 40315130)
27. Marincovich B, Castilla J, del Romero J, Garcia S, Hernando V, Raposo M, Rodriguez C. Absence of hepatitis C virus transmission in a prospective cohort of heterosexual serodiscordant couples. Sex Transm Infect 2003; 79:160-162. (Pubitemid 36469626)
28. Vandelli C, Renzo F, Romano L, Tisminetzky S, De Palma M, Stroffolini T, et al. Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol 2004; 99:855-859. (Pubitemid 39090213)
29. van de Laar TJ, van der Bij AK, Prins M, Bruisten SM, Brinkman K, Ruys TA, et al. Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. J Infect Dis 2007; 196:230-238. (Pubitemid 47047462)
30. Ghosn J, Deveau C, Goujard C, Garrigue I, Saichi N, Galimand J, et al. Increase in hepatitis C virus incidence in HIV-1-infected patients followed up since primary infection. Sex Transm Infect 2006; 82:458-460. (Pubitemid 46025186)
31. Giraudon I, Ruf M, Maguire H, Charlett A, Ncube F, Turner J, et al. Increase in diagnosed newly acquired hepatitis C in HIV-positive men who have sex with men across London and Brighton, 2002-2006: is this an outbreak? Sex Transm Infect 2008; 84:111-115. (Pubitemid 351497921)
32. Ruf M, Cohuet S, Maguire H, Brant LJ, Ramsay M, Lattimore S, Delpech V. Setting up an enhanced surveillance of newly acquired hepatitis C infection in men who have sex with men: a pilot in London and South East region of England. Euro Surveill 2008; 13.
33. Bodsworth NJ, Cunningham P, Kaldor J, Donovan B. Hepatitis C virus infection in a large cohort of homosexually active men: independent associations with HIV-1 infection and injecting drug use but not sexual behaviour. Genitourin Med 1996; 72:118-122. (Pubitemid 26130428)
34. Buchbinder SP, Katz MH, Hessol NA, Liu J, O'Malley PM, Alter MJ. Hepatitis C virus infection in sexually active homosexual men. J Infect 1994; 29:263-269. (Pubitemid 24365182)
35. Ndimbie OK, Kingsley LA, Nedjar S, Rinaldo CR. Hepatitis C virus infection in a male homosexual cohort: risk factor analysis. Genitourin Med 1996; 72:213-216. (Pubitemid 26197888)
36. Schmidt A, Vogel M, Krznaric I, Rockstroh J, Radun D, Study Group on Sexual Risk Factors for Hepatitis C. The trouble with bleeding: why do HIV-positive gay men get hepatitis C? [abstract BPD 1/7] In: 12th European AIDS Conference; 11-14 November 2009; Cologne, Germany.
37. Danta M,Brown D, BhaganiS, Pybus OG, Sabin CA, Nelson M, et al. Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 2007; 21:983-991. (Pubitemid 46684329)
38. Briat A, Dulioust E, Galimand J, Fontaine H, Chaix ML, Letur-Konirsch H, et al. Hepatitis C virus in the semen of men coinfected with HIV-1: prevalence and origin. AIDS 2005; 19:1827-1835. (Pubitemid 41546601)
39. Turner J, Aarons E, O'Farrell S, Price H, Ferns B, Copas A, Gilson R. Hepatitis C viral load in semen of HIV-positive men during acute and chronic hepatitis C infection [abstract O5]. In: Second Joint BHIVA /BASHH Conference; 20-23 April 2010; Manchester, UK.
40. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009; 136:1609-1617.
41. Scott C, Day S, Low E, Sullivan A, Atkins M, Asboe D. Un-selected hepatitis C screening of men who have sex with men attending sexual health clinics. J Infect 2010; 60:351-353.
42. Fox J, Nastouli E, Thomson E, Muir D, McClure M, Weber J, Fidler S. Increasing incidence of acute hepatitis C in individuals diagnosed with primary HIV in the United Kingdom. AIDS 2008; 22:666-668. (Pubitemid 351640605)
43. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461:798-801.
44. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010; 138:1338-1345; 1345 e1-e7.
45. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461:399-401.
46. Post J, Ratnarajah S, Lloyd AR. Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009; 66:733-756.
47. Bowen DG, Walker CM. Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 2005; 436:946-952. (Pubitemid 41191670)
48. Schnuriger A, Dominguez S, Guiguet M, Harfouch S, Samri A, Ouazene Z, et al. Acute hepatitis C in HIV-infected patients: rare spontaneous clearance correlates with weak memory CD4 T-cell responses to hepatitis C virus. AIDS 2009; 23:2079-2089.
49. Danta M, Semmo N, Fabris P, Brown D, Pybus OG, Sabin CA, et al. Impact of HIV on host-virus interactions during early hepatitis C virus infection. J Infect Dis 2008; 197:1558-1566. (Pubitemid 351706486)
50. Valdez H, Anthony D, Farukhi F, Patki A, Salkowitz J, Heeger P, et al. Immune responses to hepatitis C and nonhepatitis C antigens in hepatitis C virus infected and HIV-1 coinfected patients. AIDS 2000; 14:2239-2246.
51. Aberle JH, Formann E, Steindl-Munda P, Weseslindtner L, Gurguta C, Perstinger G, et al. Prospective study of viral clearance and CD4(R) T-cell response in acute hepatitis C primary infection and reinfection. J Clin Virol 2006; 36:24-31. (Pubitemid 44360574)
52. Chen M, Sallberg M, Sonnerborg A, Weiland O, Mattsson L, Jin L, et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology 1999; 116:135-143. (Pubitemid 29013502)
53. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994; 68:1494-1500. (Pubitemid 24065713)
54. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 2000; 288:339-344. (Pubitemid 30226196)
55. Post JJ, Pan Y, Freeman AJ, Harvey CE, White PA, Palladinetti P, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of sero-conversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004; 189:1846-1855. (Pubitemid 38657221)
56. Chapel HM, Christie JM, Peach V, Chapman RW. Five-year follow-up of patients with primary antibody deficiencies following an outbreak of acute hepatitis C. Clin Immunol 2001; 99:320-324.
57. Dowd KA, Netski DM, Wang XH, Cox AL, Ray SC. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenter-ology 2009; 136:2377-2386.
58. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, et al. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138:315-324.
59. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284:450-456. (Pubitemid 30484478)
60. Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz B, Chaplinskas S, et al. Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008; 198:1337-1344.
61. Gambotti L, Batisse D, Colin-de-Verdiere N, Delaroque-Astag-neau E, Desenclos JC, Dominguez S, et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill 2005; 10:115-117.
62. Gilleece YC, Browne RE, AsboeD,AtkinsM,MandaliaS,Bower M, et al. Transmission of hepatitis C virus among HIV-positive homosexual men and response to a 24-week course of pegy-lated interferon and ribavirin. J Acquir Immune Defic Syndr 2005; 40:41-46. (Pubitemid 41233203)
63. Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006; 20:233-240.
64. Gerlach JT, Diepolder HM, Zachoval R, Gruener NH, Jung MC, Ulsenheimer A, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastro-enterology 2003; 125:80-88. (Pubitemid 36799109)
65. Mosley JW, Operskalski EA, Tobler LH, Buskell ZJ, Andrews WW, Phelps B, et al. The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy. J Viral Hepat 2008; 15:120-128.
66. Vogel M, Page E, Matthews G, Guiguet M, Dominguez S, Dore G, et al. Use of week 4 HCV RNA after acute HCV infection to predict chronic hcv infection [abstract 640]. In: 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, California, USA.
67. Nomura H, Sou S, Tanimoto H, Nagahama T, Kimura Y, Hayashi J, et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004; 39:1213-1219. (Pubitemid 38569042)
68. Deterding K, Grüner N, Wiegand J, Buggisch P, Galle P, Spengler U, et al. Early versus delayed treatment of acute hepatitis C: the German HEP-NET Acute HCV-III Study - a randomized controlled trial [abstract 1047]. In: 44th Annual Meeting of the European Association for the Study of the Liver (EASL 2009); 22-26 April 2009; Copenhagen, Denmark.
69. Jaeckel E, Cornberg M, Wedemeyer H, Santantonio T, Mayer J, Zankel M, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345:1452-1457.
70. Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, et al. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET Acute-HCV-II Study. Hepatology 2006; 43:250-256.
71. Vogel M, Nattermann J, Baumgarten A, Klausen G, Bieniek B, Schewe K, et al. Pegylated interferon-alpha for the treatment of sexually transmitted acute hepatitis C in HIV-infected individuals. Antivir Ther 2006; 11:1097-1101. (Pubitemid 44955186)
72. Fierer D, Fishman S, Uriel A, Carriero D, Factor S, Mullen M, et al. Characterization of an outbreak of acute HCV infection in HIV-infected men in New York city [abstract 802]. In: 16th Conference on Retroviruses and Opportunistic Infections; 8-11 February 2009; Montreal, Canada.
73. Dominguez S, Ghosn J, Valantin MA, Schruniger A, Simon A, Bonnard P, et al. Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients. AIDS 2006; 20:1157-1161. (Pubitemid 43786104)
74. Kruk A. Efficacy of acute HCV treatment with peg-interferon a-2b and ribavirin in HIV infected patients [abstract TuPe1.1C01]. In: 3rd IAS Conference on HIV Pathogenesis and Treatment; 24-27 July 2005; Rio De Janeiro, Brazil.
75. Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41:31-36. (Pubitemid 41786016)
76. Vogel M, Bieniek B, Jessen H, Schewe CK, Hoffmann C, Baumgarten A, et al. Treatment of acute hepatitis C infection in HIV-infected patients: a retrospective analysis of eleven cases. J Viral Hepat 2005; 12:207-211. (Pubitemid 40342180)
77. Arends JE, Mudrikova T, Wensing MJ, Wind CM, van Baarle D, Hoepelman IM. High percentage of non-response with pegin-terferon-alfa-2a monotherapy for the treatment of acute hepatitis C in HIV infected patients [abstract H-222]. In: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; 12-15 September 2009; San Francisco, California, USA.
78. Matthews G, Grebely J, Hellard M, Yeung B, Marks P, Raw-linson W, et al. Differences in early virological decline in individuals treated within the Australian trial in acute HCV suggest a potential benefit for the use of ribavirin [abstract O60]. In: 45th Annual Meeting of the European Association for the Study of the Liver (EASL); 30 March-3 April 2010; Vienna, Austria.
79. Hare B, Marks K, Luetkemeyer A, Charlebois E, Glesby M, Talal A, et al. Kinetically guided PEG alfa-2a and RBV therapy for HIVR adults with acute HCV infection [abstract 639]. In: 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, California, USA.
80. Lambers F, van den Berk G, van der Meer J, Spijkerman I, Molenkamp R, Coutinho R, et al. Treatment outcome of acute HCV infection in HIV-infected MSM: effect of treatment length [abstract 641]. In: 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco, California, USA.
81. Calleri G, Cariti G, Gaiottino F, De Rosa FG, Bargiacchi O, Audagnotto S, et al. A short course of pegylated interferon-alpha in acute HCV hepatitis. J Viral Hepat 2007; 14:116-121. (Pubitemid 46146706)
82. Vogel M, Dominguez S, Bhagani S,Azwa A, Page E, Guiguet M, et al. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort. Antivir Ther 2010; 15:267-279.
83. Rockstroh J, Benhamou Y, Bhagani S, Bruno R, Garcia D, Mauss S, et al. European AIDS Clinical Society (EACS) Guidelines for the clinical management and treatment of chronic hepatitis B and C co-infection in HIV-infected adults: 2009. http:// www.europeanaidsclinicalsociety.org/guidelines.asp.